IP Library Granted Patent US 8,388,969
Granted Patent B2
US 8,388,969 · App. 13/224,913 · Granted Mar 5, 2013

Interleukin-1 alpha antibodies and methods of use

Inventor: John Simard (Austin, TX)
Assignee: Xbiotech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,388,969
App. No.
13/224,913
Granted
Mar 5, 2013
Kind
B2
Abstract

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Claims (1)

1. A method of killing a cell expressing human interleukin-1alpha (IL-1α), the method comprising the step of contacting a mixture of the cell and human peripheral blood mononuclear cells with an amount of a purified human IgG1 monoclonal antibody (mAb) that specifically binds to human IL-1α, wherein the amount is sufficient to kill the cell and the cell is killed, and wherein the human IgG1 mAb comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:11.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2020
From: XBIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 051769/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2011
From: SIMARD, JOHN
To: XBIOTECH, INC.
Reel/Frame 026857/0486 →
Continuity (5)
Division 12455458 · Jun 1, 2009
Provisional Application 61057586 · May 30, 2008
Provisional Application 61121391 · Dec 10, 2008
Provisional Application 61178350 · May 14, 2009
Related Publication 20120014971A1 · Jan 19, 2012